A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin

PHASE2CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

December 31, 2005

Study Completion Date

July 31, 2007

Conditions
Renal Anemia
Interventions
DRUG

FG2216

Trial Locations (27)

Unknown

Research Site, Tucson

Research Site, Little Rock

3 Research Sites, Los Angeles

Research Site, Oakland

Research Site, San Diego

Research Site, Santa Clara

Research Site, Lauderdale Lakes

Research Site, Miami

Research Site, Pembroke Pines

Research Site, Atlanta

Research Site, South Holland

Research Site, Shreveport

Research Site, Springfield

Research Site, Kalamazoo

Research Site, Pontiac

Research Site, Flushing

Research Site, Cincinnati

Research Site, Columbus

Research Site, Portland

Research Site, Allentown

Research Site, Hershey

Research Site, Pittsburgh

Research Site, Orangeburg

Research Site, Houston

Research Site, San Antonio

Research Site, Chesapeake

Research Site, Fairfax

Sponsors

Lead Sponsor

All Listed Sponsors
lead

FibroGen

INDUSTRY